I've experienced tren cough with acetate and noticed a slight urge to cough with various AAS not to the same level though.
If it was simply due to the oil itself you would think it wouldn't be called "tren cough".
Many medications can induce a sudden cough at times. Rapid IV push of Diphenhydramine (H1 receptor antagonist) can frequently induce a sudden severe cough much like that from tren. Fentanyl can also induce severe cough which can be reduced by an H1 antagonist like diphenhydramine, (go figure).
It's possible it may have an allergic reaction element as well.
The nature of the receptor mediating stimulant eff... [J Physiol. 1979] - PubMed - NCBI
"The nature of the receptor mediating stimulant effects of histamine on rapidly adapting vagal afferents in the lungs."
Found that Chlorpheniramine(H1 agonist like Benadryl) caused a "brief stimulation of rapidly adapting receptors(RAR)."
Physiology and plasticity of putative co... [Pulm Pharmacol Ther. 2002] - PubMed - NCBI
Physiology and plasticity of putative cough fibres in the Guinea pig.
"Cough is initiated by activation of afferent nerve fibers with rapidly adapting receptors (RAR) that conduct action potentials in the Adelta range. In addition, various stimuli that activate airway unmylenated C-fibres evoke cough reflexes. "
Best way to minimize it is to inject slowly. If you notice the urge to cough then slow down and or stop for a moment until it passes.
Found a little more info on sudden onset cough from intramuscular injections, this one from the IM inj of NEBIDO that supports the oil depot inj theory, but also brings up allergic/anaphlactic response as well.
**broken link removed**
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
"The FDA has expressed a concern about a relatively small number of
patients in European post-marketing use who have experienced respiratory
symptoms immediately following the intramuscular injection of NEBIDO 1000
mg, 4 cc injection volume, (versus the 750 mg, 3 cc injection volume used
in the United States).
The Company believes and the FDA concurs that the
reaction is likely the result of a small amount of the oily solution
immediately entering the vascular system from the injection site, a known,
rare complication of oil-based depot injections."
"The phenomenon is characterized by short-term reactions involving an
urge to cough, coughing episodes or a shortness of breath. In rare cases
the reaction has been classified as serious or the patient experiences
other symptoms such as dizziness, flushing or fainting."
"In addition, the FDA believes that four cases in the
European post-marketing experience may have an allergic, anaphylactoid
component, although the Company believes these cases were improperly
classified and represent the same oil-based phenomenon."